Phase I and Pharmacokinetic Study of PKC412, an Inhibitor of Protein Kinase C

Abstract

PKC412 can be safely administered by chronic oral therapy, and 150 mg/d is suitable for phase II studies. The pharmacokinetics and lack of conventional toxicity indicate that pharmacodynamic measures may be additionally needed to optimize the drug dose and schedule.